[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinicopathologic Reports, Case Reports, and Small Case Series
September 2001

Intravitreal Triamcinolone for Refractory Cystoid Macular Edema Secondary to Birdshot Retinochoroidopathy

Arch Ophthalmol. 2001;119(9):1380-1383. doi:

Birdshot retinochoroidopathy is a chronic, bilateral uveitic disorder. Originally described by Ryan and Maumenee,1 it is characterized by posterior segment inflammation in the presence of multiple depigmented choroidal lesions symmetrically scattered throughout the postequatorial retina. The cause is presumed to be autoimmune and more than 90% of patients test positive for the HLA-A29 serotype.2 Approximately half of affected eyes develop cystoid macular edema (CME), and this represents a major cause of considerable visual loss from this condition.3 A rationale for treatment with corticosteroids has been established based on the inflammatory nature of the disease. However, systemic and periocular corticosteroids have failed to produce significant improvement in most treated patients.4 We report 2 cases of refractory CME secondary to birdshot retinochoroidopathy that were successfully treated with intravitreal injections of triamcinolone acetonide.